Back to results
US 2021/0059984 A1Published application
Method and composition for reversing cognitive impairments and loss using sglt2 inhibitors
AssigneeTaisho Pharmaceutical Co., Ltd.
InventorsFan FAN, Richard J. ROMAN, Shaoxun WANG
Life of this patent
Estimating the term…
Abstract
A new drug useful in the treatment of cognitive impairment is provided, in which an effective amount of luseogliflozin or a pharmaceutically acceptable salt thereof, or a hydrate of luseogliflozin or the salt is contained as an active ingredient.
Claims4
A method of treating cerebrovascular dementia which comprises administering to a subject in need thereof an effective amount of luseogliflozin or a pharmaceutically acceptable salt thereof.
(canceled)
Dependencies are inferred from the claim text.